Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -164,981 | -68,357 | -23,202 | -25,828 | -6,800 |
| Depreciation Amortization | 3,519 | 3,024 | 925 | 127 | 38 |
| Accounts receivable | 2,538 | 531 | -2,818 | -339 | N/A |
| Other Working Capital | 10,550 | -25,387 | 1,781 | 81,368 | 1,534 |
| Other Operating Activity | 52,135 | 20,096 | -31,996 | 4,100 | 435 |
| Operating Cash Flow | $-96,239 | $-70,093 | $-55,310 | $59,428 | $-4,793 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,773 | -7,814 | -3,016 | -1,154 | N/A |
| Purchase Of Investment | N/A | -500 | N/A | N/A | N/A |
| Sale Of Investment | N/A | N/A | 35,000 | N/A | N/A |
| Other Investing Activity | 0 | 0 | -100 | 0 | 0 |
| Investing Cash Flow | $-2,773 | $-8,314 | $31,884 | $-1,154 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 35,010 | 38,239 | N/A |
| Common Stock Issued | 315,991 | 2,608 | 35,034 | 243 | 22 |
| Common Stock Repurchased | -57 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 113,176 | 58,251 | 5,101 |
| Financing Cash Flow | $315,934 | $2,608 | $183,220 | $96,733 | $5,123 |
| Exchange Rate Effect | -22 | 41 | -235 | 9 | 254 |
| Beginning Cash Position | 242,912 | 318,670 | 155,961 | 945 | 361 |
| End Cash Position | 459,812 | 242,912 | 315,520 | 155,961 | 945 |
| Net Cash Flow | $216,900 | $-75,758 | $159,559 | $155,016 | $584 |
| Free Cash Flow | |||||
| Operating Cash Flow | -96,239 | -70,093 | -55,310 | 59,428 | -4,793 |
| Capital Expenditure | -2,773 | -7,814 | -3,016 | -1,154 | N/A |
| Free Cash Flow | -99,012 | -77,907 | -58,326 | 58,274 | -4,793 |